top of page

Cambridge, UK based Harness Therapeutics, which topped up its seed financing this week, aims to use its oligo platform to treat Huntington's by upregulating the FAN1 nuclease across the brain

Jan 29, 2025
1 min read

CEO Jan Thirkettle describes the company's approach to upregulating genes for neurodegenerative diseases and how Harness is out front in targeting FAN1 for Huntington's.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page